Background {#Sec1}
==========

Helicobacter pylori (*H. pylori*) is a gram-negative spiral bacterium which is found abundantly in the stomach. The *H. pylori* infection is one of the most common chronic infections in the world, so that more than 50% of the world's population are infected with this infection \[[@CR1], [@CR2]\]. It is now known that *H. pylori* is responsible for most cases of peptic ulcer disease. Also, the different studies highlighted that it is associated with other important gastrointestinal diseases such as chronic gastritis, gastric adenocarcinoma, and MALT lymphoma which are recognized as a major public health concern in the world \[[@CR3], [@CR4]\]. In addition to the role of *H. pylori* in gastrointestinal disorders, some researches have suggested the potential role of this bacterium in the development of non-gastrointestinal disorders such as cardiovascular diseases and metabolic syndrome especially diabetes \[[@CR5]--[@CR7]\]. Diabetes is the most common metabolic disease in the world and responsible for about 4 million deaths per year. The global prevalence of diabetes was 4.6% equivalent to 285 million in adults for 2010, which this number has reached 371 million in 2012, and is expected to reach 552 million by 2030 \[[@CR8]--[@CR10]\].

As mentioned above, one of the factors that may affect incidence of diabetes is *H. pylori*. The relationship between *H. pylori* infection and diabetes was introduced in 1989 \[[@CR11]\]. It has been suggested that the *H. pylori* may be contributed to the incidence of cardiovascular disease and diabetes through elevations in inflammatory cytokines levels such as C-reactive protein (CRP) and interleukin-6 \[[@CR11]--[@CR13]\]. In general, various studies have investigated the role of *H. pylori* in the pathogenesis of diabetes and its complications, but the results are inconsistent with each other. For example, some case-control studies have reported higher prevalence of *H. pylori* in patients with diabetes \[[@CR14], [@CR15]\]. Also, several cross-sectional studies have shown a significant statistical association between *H. pylori* and diabetes \[[@CR3], [@CR15]\]. However, some studies in this regard have shown that there is no significant association between diabetes and prevalence *H. pylori* infection \[[@CR2], [@CR16], [@CR17]\].

Therefore, the association between *H. pylori* infection and the risk of diabetes is still controversies. Hence, this systematic review and meta-analysis study was designed to identify the possible association between *H. pylori* infection and the risk of diabetes.

Methods {#Sec2}
=======

This systematic review and Meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) and Strengthening the Reporting of Observationally Studies in Epidemiology (STROBE) guidelines for reviews of analytical observational studies (case-control) \[[@CR18]--[@CR20]\].

Search terms and complex search syntax {#Sec3}
--------------------------------------

All original published articles were searched from January 1990 to March 2019 without language limitations in international databases, including Medline (PubMed), Web of Sciences, Scopus, EMBASE, Cochrane, Ovid and CINHAL. The keywords were Diabetes, Diabetes Mellitus (type 1 and 2), Insulin Dependent, IDDM, NIDDM, Noninsulin Dependent, Insulin Sensitivity, Helicobacter pylori, Campylobacter pylori, and H Pylori. Two reviewers (YM and RR) abstracted data independently and reached consensus on all items. Inclusion and exclusion criteria were set by two researchers separately (YM and RR) (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Flow Diagram of the Literature Search and Study Selection

Eligibility criteria {#Sec4}
--------------------

A published study had to meet the following inclusion criteria:

\(1\) case-control, nested case control studies, (2) human population, and (3) Helicobacter pylori infection was exposure variable. Case reports, reviews, animal studies, and cohort studies were removed from the tabulation. The authors resolved all disputes during the collection, compilation, and analysis of data.

Data extraction {#Sec5}
---------------

Two reviewers (YM and RR) independently extracted the data. A structured checklist was used for the extraction of information including; 1) name of first author, 2) date of publication, 3) country, 4) study subjects, 5) age of patients, 6) sample size, 7) type of diabetes, 8) mean of HbA1C, 9) duration of diabetes, 10) measurement of association, 11) controlled variables, 12) and method of bacteria detection. In addition, type of instruments (detection of *H. pylori*) was extracted from each study in case of reporting. A data extraction form was created based on our group discussion and piloted according to 10 different types of studies. Then, it was modified and used by the data extractor. All process from systematic search to final data extraction were followed independently by two research experts (Kappa statistic for agreement for quality assessment; 0.75). Any disagreement was assessed by both and if a consensus was not reached, a third author (LS) evaluate the study. The qualities of all studies were assessed by Modified Newcastle-Ottawa Scale for Case Control studies \[[@CR21]\].

Statistical analysis {#Sec6}
--------------------

Logarithm and standard error logarithm odds ratio (OR) were used for the meta-analysis. DerSimonian and Laird method was used to compute the pooled estimate of odds ratio (OR) with confidence interval (CI 95%) using random models \[[@CR22]\]. Because the test for heterogeneity was statistically significant in some analyses, the random effects models were used to estimate OR. In this study, w Cochran's Q test and I2 statistic were used to evaluate statistical heterogeneity between studies \[[@CR23]\]. In addition, a meta-regression and subgroup analysis were performed to assess the source of heterogeneity between studies. Moreover, publication bias was assessed by funnel plot and Egger test \[[@CR24], [@CR25]\]. Statistical analysis was performed using STATA 14.0 (Stata Corp, College Station, TX, USA), and statistical significance was set at *p* \< 0.05.

Results {#Sec7}
=======

Study characteristics {#Sec8}
---------------------

The first step of search in electronic databases yielded 2027 publications and 200 studies identified through other sources. In the final step, after removing the duplicates, reviewing by title, abstract and full text and considering the inclusion and exclusion criteria, 41 studies were selected for the meta-analysis of pooled association between *H. pylori* infection and the risk of diabetes (Fig. [1](#Fig1){ref-type="fig"}). Characteristics of included studies in this meta-analysis are reported in Table [1](#Tab1){ref-type="table"}. The total sample size in the 41 studies that reported the association between *H. pylori* infection and the risk of diabetes in case and control was 4327 and 5232, respectively. Also, 11 studies reported association between *H. pylori* infection with DM. Other primary studies reported association between *H. pylori* infection with type 1 and 2 diabetes. A total of 41 studies were included in this meta-analysis, of which 20 were conduct in European, 12 were in Asian, 7 studies done in African and 2 in American (Table [2](#Tab2){ref-type="table"}). Of the 41 studies, 18 showed statistically significant between *H. pylori* infection and the risk of diabetes. Table 1The main characteristics of Case -- Control studies of the effect of H pylori on risk of diabetes*AuthorsYearsCountryControl subjects(selection methods)AgeSample sizeType of Diabetic*\
*(Mean HbA1C)*\
*(Duration of disease)Measurement of association*\
*Odds Ratio*\
*(CI 95%)Controlled variablesBacteria detectionNOS*\
*Score*Małecki, M. et al. \[[@CR26]\]1996PolandNon-diabetic subjects17--80139 (Control:100 & Case: 39)DM (−)(8 Year)0.33(0.18, 0.59)--Histology or biopsy6Pocecco, M. et al. \[[@CR27]\]1997ItalyAdmitted for minor extra-abdominal surgery with no history of abdominal pain16379\[Control:310 & Case: 69\]DM(−)(−)3.13(2.08, 4.70)Age, sex, education and economicRapid urease test6Gentile, S \[[@CR28]\].1998ItalyNon-diabetic subjects52328 (Control:164 & Case: 164)T2DM(8.3 ± 1.4)1.77(1.35, 2.31)Age, sex and body weightHistology or biopsy7De Luis, DA \[[@CR29]\]1998SpainThe control subjects were healthy volunteers, with similar age and sex-distribution that the diabetic patients25180Control: 100 & Case: 80T1DM (−)(3.1Year)1.36(0.98, 1.87)Age and sexAnti-*H. pylori* antibody6Gasbarrini, A.et al. \[[@CR30]\]1998ItalyHealthy subjects35166\[Control: 50 & Case:116\]DM(−)(19 year)1.04(0.85, 1.28)Age and sex13C or 14C urea breath test6Salardi, S.et al. \[[@CR31]\]1999ItalyChildren with minor endocrine disorders.12339\[Control: 236 & Case:103\]T1DM(−)(−)1.47(0.99, 2.18)AgeAnti H. pylori antibody7Arslan, D. et al. \[[@CR32]\]2000TurkeyNon-diabetic subjects12130 (Control: 42 & Case: 88)T1DM (11.08 ± 3.17)(3.85 Year)1.38(1.08, 1.75)--Anti-H. pylori antibody6Dore, MP. et al. \[[@CR33]\]2000ItalyBlood donors from the same geographic area12--75891\[Control: 506 & Case: 385\]DM(greater than 1 year)1.16(1.00, 1.35)age and socioeconomic statusAnti-H. pylori antibody8Senturk, O. et al. \[[@CR34]\]2001TurkeyNondiabetic patients undergoing upper diagnostic endoscopies54.1140\[Control: 73 & Case: 67\]T2DM(6.42 ± 0.97)(4.5 year)1.39(0.78, 2.48)Age and socioeconomicHistology or biopsy7Ravera, M.et al. \[[@CR35]\]2001UgandaDyspeptic patients without diabetic--132\[Control110: & Case: 22\]DM(−)(−)1.22(0.33, 4.49)--Histology or biopsy6Ko, G. T.et al. \[[@CR36]\]2001ChineWith upper GI symptoms in whom49.9118\[Control55: & Case: 63\]T2DM(8.25 ± 2.22) (6.2 year)0.90(0.64, 1.26)Age and sexRapid urease test6Marrollo M.et al. \[[@CR37]\]2001ItalyNon diabetic dyspeptic patients63191\[Control: 117& Case: 74\]DM(−)(−)1.54(1.05, 2.27)Age and sexRapid urease test and Histology or biopsy6Quatrini, M.et al. \[[@CR38]\]2001ItalyDyspepsia patients58142\[Control: 71 & Case: 71\]DM(−)(−)1.63(1.12, 2.38)Age and sex13C or 14C urea breath test7Cenerelli, S. et al. \[[@CR39]\]2002ItalyControl subjects were first selected on the basis of the admission criteria of the senieur protocol.5573Control: 43 & Case: 30)T2DM (6.1 ± 1.8)(3.1Year)1.04(0.60, 1.80)--13C or 14C urea breath test7Maule, S.et al. \[[@CR40]\]2002ItalyIndividuals without diabetes46--7562\[Control:31 & Case: 31\]T2DM(7.1 ± 1.4)(−)1.65(0.92, 2.97)Age13C or 14C urea breath test8Candelli, M. et al. \[[@CR41]\]2003ItalyThe control Group was selected normal healthy adolescent17268Control: 147 & Case: 121)T1DM (8.2 ± 1.4)(6.7 Year)0.97(0.72, 1.30)Sex, age and social classRapid urease test,Histology or biopsy7Gulcelik, N. E.et al. \[[@CR4]\]2005TurkeyDyspeptic non diabetic subjects51.9149\[Control: 71 & Case: 78\]T2DM(8.2 ± 1.4)1.92(1.29, 2.86)Age and BMIHistology or biopsy7Jaber, S. M.et al. \[[@CR42]\]2006Saudi ArabiaHealthy children\> 10604\[Control:543 & Case: 61\]T1DM(−)(−)1.60(0.98, 2.63)--Anti H. pylori antibody6Bener, A. et al. \[[@CR43]\]2007QatarNon-diabetic subjects48420 (Control:210 & Case: 210)T2DM(6.9 ± 1.4)(−)5.03(3.90, 6.47)Age and sexAnti-H. pylori antibody7Demir, M. et al. \[[@CR44]\]2008TurkeyThe control Subjects were selected in the gastroenterology clinics52283Control: 142 & Case: 141T2DM(−)(6 year)1.07(0.84, 1.36)Age and sexRapid urease test and Histology or biopsy7Ariizumi, K. et al. \[[@CR45]\]2008Japannon-diabetic subjects without upper GI tract disorders62134\[Control: 67 & Case: 67\]DM(−)(15.1 year)0.74(0.53, 1.03)age and sex-matchedAnti H. pylori antibody,Rapid urease test, Histology or biopsy8Hamed, S. A.et al. \[[@CR46]\]2008EgyptSubjects with neither history nor clinical evidence of gastrointestinal problems; vascular, inflammatory, or neurologic diseases.47.6140\[Control:60 & Case: 80\]DM(−)(9.2 year)1.29(0.83, 2.01)Age and sexAnti H. pylori antibody8Cabral, V. L. R. et al. \[[@CR47]\]2009BrazilThe control Group was selected normal healthy adolescent1745Control: 30 & Case: 15)T1DM (−)(−)0.52(0.21, 1.29)--Histology or biopsy7Lazaraki, G. et al. \[[@CR48]\]2009Greecenon-smoking, non-diabetic with of dyspepsia6579\[Control: 30 & Case: 49\]T2DM(−)(3 year)0.99(0.70, 1.40)Age, sex, H. pylori-infection, degree of gastritisRapid urease test and Histology or biopsy7Krause, I. et al. \[[@CR49]\]2009ColombiaIndividuals had no clinical diabetes, nor islet cell autoantibodies16.0180\[Control: 123: & Case: 57\]T1DM(−)(8.8 year)0.44(0.29, 0.66)--Anti-H. pylori antibody6Devrajani, BR. et al. \[[@CR15]\]2010PakistanNon diabetic individuals with positive or negative Helicobacter pylori infection53148\[Control: 74 & Case: 74\]T2DM(−)(5 years)1.64(1.11, 2.43)--Stool antigen test7Ibrahim, A. et al. \[[@CR50]\]2010EgyptDyspeptic non diabetic subjects45200\[Control: 102 & Case: 98\]T2DM(8.57 ± 0.79)(−)0.94(0.71, 1.25)--Rapid urease test, Histology or biopsy7El-Eshmawy, M. M. et al. \[[@CR51]\]2011EgyptNon-diabetic subjects20242 (Control:80 & Case: 162)T1DM(8.2 ± 1.75)(7.29 Year)1.63(1.25, 2.11)Age, sex, geographic area and socioeconomic statusAnti-H. pylori antibody7De Block, C. E. M. et al. \[[@CR52]\]2012BelgiumOne-hundred sex- and age-matched controls were tested for H. pylori serology.40329Control: 100 & Case: 229)T1DM (7.8 ± 1.0)(18 Year)0.86(0.74, 1.02)Age and sexAnti-H. pylori antibody &Rapid urease test and Histology or biopsy7Candelli, M. et al. \[[@CR53]\]2012ItalyHealthy children19.8174\[Control: 99 & Case: 75\]T1DM(8.8 ± 0.80)(−)1.96(1.40, 2.75)Age, sex and socio-economic13C or 14C urea breath test6Jafarzadeh, A.et al. \[[@CR54]\]2012IranHealthy individuals42.86200\[Control: 100 & Case: 100\]T2DM(−)(−)1.03(0.74, 1.42)AgeAnti H. pylori IgG6Keramat, F. et al. \[[@CR55]\]2013IranNon-diabetic subjects51158 (Control: 79 & Case: 79)DM (8.96 ± 1.82)(2.78 Year)1.29(0.89, 1.88)Age and sexAnti-H. pylori antibody &Rapid urease test and Histology or biopsy8Zekry, O. A. et al. \[[@CR56]\]2013EgyptHealthy children and adolescents12.53120\[Control: 60 & Case: 60\]T1DM(7.75 ± 1.67)(9.25 year)1.69(1.21, 2.35)Age and sexAnti-H. pylori antibody8Chobot, A. et al. \[[@CR57]\]2014PolandThis group was enrolled from a large cohort of children13.4447\[Control: 298 & Case: 149\]T1DM(7.69 ± 1.63)(4.6 year)0.74(0.48, 1.15)Age- and sex13C or 14C urea breath test8Fayed, SB. et al. \[[@CR58]\]2014Egypthealthy normal volunteers12.2106\[Control:53 & Case: 53\]T1DM(9.6 ± 1.6)(12.2 year)1.80(1.14, 2.84)Age and sexAnti H. pylori antibodies7Zhou, F. et al. \[[@CR17]\]2015ChinaNon-diabetic subjects with dyspepsia symptoms45253 (Control:65 & Case: 188)T2DM(8.2 ± 1.9)1.15(0.99, 1.33)Age and sexAnti-H. pylori antibody&Rapid urease test9Bajaj, S. et al. \[[@CR3]\]2015IndiaThe control group comprised of age, sex, socioeconomic status, and education matched normal healthy volunteers\> 18140Control: 60 & Case: 80)T2DM (8.2 ± 1.2)(4.2 Year)1.53(1.04, 2.24)Age, sex, socioeconomic status, and educationAnti-H. pylori antibody &Rapid urease test and Histology or biopsy8Bazmamoun, H. et al. \[[@CR59]\]2016IranNon-diabetic subjects10160 (Control: 80 & Case: 80)T1DM (8.00 ± 0.65)(2.72 Year)1.50(1.09, 2.07)Age, sex, socioeconomic statusAnti-H. pylori antibody8Osman, S. M.et al. \[[@CR60]\]2016SudanHealthy children1--18180\[Control: 90 & Case: 90\]T1DM(−)(6 month)0.97(0.71, 1.33)age and sexAnti-H. pylori antibody8Alzahrani, S. et al. \[[@CR61]\]2017Saudi ArabiaNon-diabetic subjects49842 (Control:421 & Case: 421)DM (6.1 ± 0.6)1.01(0.88, 1.16)Age,sex, race,DPP intervention, length of follow-up time, body mass index, alcohol consumption, physical activity and smokingAnti-H. pylori antibody&Rapid urease test9Vaishnav, B. et al. \[[@CR62]\]2018IndiaNon diabetic with dyspepsia56287\[Control: 140 & Case:147\]T2DM(8.4 ± 1.0)(7.59 year)1.89(1.51, 2.36)--Rapid urease test8Table 2Summary odds Ratio (OR) Estimates \[95% confidence intervals (CIs)\] for Case--Control studies Conducted on the Association Between Helicobacter pylori and Risk of diabetes by Type of diabetes, Continent, Mean of HbA1C, Duration of Diabetes, Method of detection bacteria, NOS score and AgeSubgroupNumber of studiesSummery Odds Ratio (95% CI)Between studiesBetween subgroupsI^2^*P*~heterogeneity~QQ*P*~heterogeneity~Type of diabetes Diabetes Mellitus111.17 (0.94--1.45)82.5%0.00011.43 Type 1 Diabetes151.19 (0.98--1.45)81.6%0.00011.753.590.0001 Type 2 Diabetes151.43 (1.11--1.85)90.0%0.00012.72Continent Asian121.41 (1.05--1.88)93.2%0.00012.29 American20.45 (0.31--0.66)0.0%0.7284.123.590.001 African71.32 (1.05--1.66)61.0%0.0182.40 European201.26 (1.08--1.47)80.3%0.00012.94Mean of HbA1C^a^ 6--891.40 (0.92--2.13)95.0%0.0011.55 8 \<131.41 (1.20--1.64)73.7%0.0014.333.590.0001Duration of Diabetes^a^ 0--3 Y71.18 (1.06--1.31)0.0%0.4503.07 4--7 Y101.15 (0.95--1.38)69.1%0.0011.453.590.001 8 \< Y91.09 (0.79--1.51)91.0%0.00010.55Method of detection bacteria Invasive Tests181.07 (0.93--1.23)73.2%0.00011.00 Non- Invasive Test231.45 (1.19--1.76)88.5%0.00013.703.590.0001Age^a^ 10--30 Y151.30 (1.05--1.62)81.9%0.00012.37 30--60 Y181.34 (1.09--1.65)91.3%0.00012.773.590.0001 60 \< Y31.03 (0.68--1.57)76.4%0.0140.15NOS Score 6111.14 (0.85--1.53)87.7%0.00010.86 7161.42 (1.10--1.82)89.0%0.00012.72 8121.24 (1.00--1.53)81.6%0.00011.963.590.0001 921.08 (0.95--1.22)35.0%0.2161.14Largely diabetes mellitusAll statistical tests were 2-sided^a^other studies not reported HbA1C, duration of diabetes,

The pooled estimate of the association between *H. pylori* infection with diabetes mellitus was 1.27 (95% CI 1.11 to 1.45, *P* = 0.0001, I^2^ = 86.6%) (Fig. [2](#Fig2){ref-type="fig"}), but since the CI of test (Egger's test) included zero, no significant bias occurred in the publication of the results (Egger's test = 1.579, *P* = 0.073, 95% CI − 0.154 to 3.312) (Fig. [3](#Fig3){ref-type="fig"}). Fig. 2Association between Helicobacter pylori and Risk of diabetes (DM, T2DM and T1DM)Fig. 3Funnel plot of association between Helicobacter pylori and Risk of diabete**s**

Subgroup analysis {#Sec9}
-----------------

Based on the random effect model, the effect of *H. pylori* infection on diabetes mellitus, type 1 and type 2 diabetes was 1.17 (95% CI 0.94 to 1.45), 1.19 (95% CI 0.98 to 1.45), and 1.43 (95% CI 1.11 to 1.85) respectively. Effect size of *H. pylori* infection on type 2 diabetes was higher than type 1 and diabetes mellitus (Table [2](#Tab2){ref-type="table"}). Some of the primary studies did not mention that the study population was type 1 or type 2, therefore we decided to include these types of studies as diabetes mellitus group in subgroup analysis.

Subgroup analysis by the geographical regions showed in Asian population risk of the effect of *H. pylori* infection on diabetes was higher than other population. In addition, the relationship between *H. pylori* and the risk of diabetes according to age showed that risk in individual with 30 to 60 years was 1.34 (95% CI 1.09, 1.65), in 10 to 30 years, and upper 60 years was 1.34 (95% CI 1.05, 1.62) and 1.03 (95% CI 0.93, 3.23), respectively (Table [2](#Tab2){ref-type="table"}).

The effect of *H. pylori* infection on diabetes mellitus by non- invasive testes detected was higher than invasive tests methods, (Table [2](#Tab2){ref-type="table"}).

Discussion {#Sec10}
==========

Our systematic review and meta-analysis suggest that there is a positive association between *H. pylori* infection and diabetes. The results showed a significant statistical association between *H. pylori* infection and the risk of diabetes (overall OR: 1.27; 95% CI: 1.11--1.45). The results of subgroup analysis by type of diabetes revealed a significant association between *H. pylori* infection and the risk of type 2 diabetes (OR: 1.43; 95% CI: 1.11--1.85). However, this meta-analysis showed a positive relationship between *H. pylori* and the risk of type 1 diabetes (OR: 1.19; 95% CI: 0.98--1.45) and diabetes mellitus (OR: 1.17; 95% CI: 0.94--1.45) but statistically were not significant. Subgroup analysis by the geographical regions showed a significant direct relationship between *H. pylori* and the risk of diabetes in Asian, Europe and Africa but in the American population this association was negative. In addition, in subgroup analysis, the relationship between *H. pylori* and the risk of diabetes was different based to age, level of HbA1C, duration of diabetes and methods for *H. pylori* detection. This suggests that these factors could be an important source of heterogeneity in the studies included in the meta-analysis.

Our meta-analysis suggests that *H. pylori* infection may increase the risk of diabetes by up to 27%. These findings are consistent with the results of several meta-analysis studies that have been done in this field. According to our knowledge, three other meta-analysis studies have been conducted regarding the association between *H. pylori* and diabetes. The first study which has been conducted by Jun-Zhen Li on 79 studies with 57,397 individuals from January 1996 to January 2016, showed that the prevalence of *H. pylori* infection in diabetes mellitus patients was significantly higher than non-diabetic (OR: 1.69; 95% CI: 1.47--1.95), however, this difference was only significant for type 2 diabetes (OR: 2.05; 95% CI: 1.67--2.52) \[[@CR2]\]. The second study that was carried out by FENG WANG on 39 eligible studies for meta-analysis form 1997 and 2012, revealed that the *H. pylori* infection also associated with increased risks of type 1 (OR: 1.99, 95% CI 1.52--2.60) and type 2 diabetes (OR: 2.15, 95% CI 1.81--2.55) \[[@CR63]\]. In the third meta-analysis study by Zhou et al. on 41 articles and 14,080 participants, the results reveled a significant association between *H. pylori* infection and increased risks of diabetes (OR: 1.33; 95% CI: 1.08--1.64) \[[@CR64]\]. However, some studies did support significant association between *H. pylori* infection and the risk of diabetes \[[@CR16], [@CR65]\].

Several mechanisms have been proposed for the relationship between *H. pylori* infection and risk of diabetes. Inflammatory cytokine may lead to induce phosphorylation of serine residues on the insulin receptor substrate and subsequently this phenomenon may impair the interaction between the substrate and the insulin receptors due to impaired insulin function \[[@CR7], [@CR66]\]. Also, Lipopolysaccharides from gram-negative bacteria such as *H. pylori* may activate Toll-like receptors and subsequently insulin resistance occurs \[[@CR67]\]. All of these events can lead to reduced blood sugar control and consequently diabetes mellitus. In addition, the presence of bacterial infections can lead to microvascular failure and eventually incidence of atherosclerosis \[[@CR68]\].

In subgroup analysis of geographical regions by the type of continent, we explored a significant direct relationship between *H. pylori* and the risk of diabetes in Asian, Europe and Africa but not in the American, however there was still high heterogeneity within these subgroups, therefore the interpretation of this negative result would be difficult. This was consistent with study of Jun-Zhen Li et al. that have shown *H. pylori* infection is significantly higher in patients with diabetes residing in Asia and Europe than in Africa and the American \[[@CR69]\]. Also, Wang F et al. reported *H. pylori* can increase the risk of diabetes in European, Middle East and South Asia \[[@CR63]\]. But, study carried out by Zhou et al. found *H. pylori* infection is significantly higher in patients with diabetes residing in only Asia \[[@CR64]\]. This difference in various continents may be due to differences in sample size, different diagnostic methods and different medical care conditions. However, to determine the precise effect of geographical location on the association between *H. pylori* and diabetes risk, it is suggested to carry out further studies to look at the role of genetic and environmental factors particularly in migrant populations.

Also, in subgroup analysis, we found a significant direct relationship between *H. pylori* and the risk of diabetes in mean of HbA1C \> 8. This result was in line with the results of other studies in this field. For example, the study by Ming-Chia Hsieh et al. revealed that there is a significant and direct statistical relationship between prevalence of *H. pylori* and serum HbA1c levels but not fasting glucose levels after adjusting for sex, age, BMI and family history of diabetes mellitus, so that the positive *H. pylori* group had significantly higher serum HbA1c levels compared to the negative *H. pylori* group (5.78% vs. 5.69%, *p* = 0.007) \[[@CR70]\]. Another study in China revealed individuals with *H. pylori* infection had a higher level HbA1C than those who did not \[[@CR71]\]. Considering the HbA1c is a valid and reliable indicator for estimating average blood sugar in long-term, it seems to be more valid to evaluate the effect of chronic *H. pylori* infection on blood glucose regulation, because fasting glucose levels are subject to daily changes such as diet and physical activity which these fluctuations may impair any association between *H. pylori* infection and glucose regulation \[[@CR72]--[@CR74]\]. In addition, in subgroup analysis relationship between *H. pylori* and the risk of diabetes was different by age. This finding was consistent with results of other reports, because the different studies have shown that the prevalence of *H. pylori* infection varies with age \[[@CR75]\].

Finally, association between *H. pylori* and the risk of diabetes was different by methods for *H. pylori* detection in subgroup analysis. This suggests that this factor could be an important source of heterogeneity in the studies included in the meta-analysis, because different methods of detection for *H. pylori* had different accuracy and precision in such cases the serological tests of anti- *H. pylori* IgG or/and IgA antibody in serum may be reported with different degree of false positives \[[@CR76], [@CR77]\]. As a result, association *H. pylori* and the risk of diabetes may be different according to the method of diagnosis of infection.

Strengths and limitations {#Sec11}
-------------------------

This study similar to other studies has some limitations and strengths.

One of the issue which make distinguish this meta-analysis with the previous ones is dealing with heterogeneity through a subgroups analysis based on type of diabetes, geographical regions, age, and level of HbA1c, duration of diabetes and detection methods of *H. pylori*. Another strength point of our meta-analysis is considering as much as reported and published studies in comparison with other systematic reviews (41 studies) that we were unable to investigate the exact effect of the publication bias.

Also, this study has some limitations. Firstly, missing potential studies e.g. limiting full- text review to English language articles may be lead to some degree of selection bias. Secondly, all studies included in meta-analysis were case-control, hence, the design and implementation of cohort studies are essential for detailed assessment of the association between *H. pylori* infection and diabetes. Thirdly, personal judgments may be effect on search of articles, data extraction and assessment of included articles in meta-analysis.

Conclusion {#Sec12}
==========

According to this systematic review & meta-analysis, it can be concluded that *H. pylori* infection could be a potential risk factor for diabetes particularly type 2 diabetes, however further prospective studies are necessary to show the direction of this association.
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